FDA reviews GSK's response to Complete Response letter for Horizant
GlaxoSmithKline and XenoPort, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review GSK's response to FDA's Complete Response letter for Horizant (gabapentin...
View ArticleXenoPort third quarter net loss decreases to $19.9 million
XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same...
View ArticleFDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome
GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of...
View ArticleGlaxoSmithKline, XenoPort receive FDA approval for Horizant to treat RLS
On April 6, the U.S. Food and Drug Administration approved Horizant Extended Release Tablets, a once-daily treatment for moderate-to-severe restless legs syndrome.
View ArticleXenoPort first quarter revenues increase to $10.4 million
XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.
View ArticleFDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN
GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the...
View ArticleXenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3...
XenoPort, Inc. announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil for the treatment of patients with spasticity due to multiple sclerosis.
View ArticleXenoPort reports net loss of $19.1 million for fourth quarter 2013
XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same...
View ArticleXenoPort initiates XP23829 Phase 2 clinical trial in patients with psoriasis
XenoPort, Inc. announced today that it has initiated a Phase 2 clinical trial of XP23829, its proprietary investigational next-generation fumaric acid product candidate. The trial is a multi-center,...
View ArticleAmerican Pain Society releases new post-surgical pain management guideline
The American Pain Society has released a new evidence-based clinical practice guideline, appearing in The Journal of Pain, with 32 recommendations to help clinicians achieve optimal pain management...
View Article
